2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment Approaches
2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic TherapyПодробнее
2022 KU Post San Antonio Review | Monday Morning Practice Implications: Q&A and Case Discussion 2Подробнее
San Antonio Breast Cancer Symposium 2022 highlightsПодробнее
2022 KU Post San Antonio Review | Updates in Locoregional TherapyПодробнее
Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment StrategiesПодробнее
2022 KU Post San Antonio Review | Breast Cancer Risk Assessment and Reduction: What's NewПодробнее
2022 KU Post San Antonio Review | (Neo)adjuvant Therapy for Triple Negative Breast CancerПодробнее
2022 KU Post San Antonio Review | Monday Morning Practice Implications: Q&A and Case Discussion 1Подробнее
Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее
Metastatic Hormone Positive Breast Cancer | 2023 KU Breast Cancer Year in Review ConferenceПодробнее
Spotlight Session 8 HER2 Positive Breast Cancer Novel therapies for HER2+ advanced breast cancerПодробнее
ASCO 2022: Metastatic Breast Cancer Drug Therapy RecapПодробнее
The evolution of HER2 targeting in metastatic breast breast cancerПодробнее
Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast CancerПодробнее
Highlights from the San Antonio Breast Cancer Symposium 2022Подробнее
2022 West Oncology Conference | Breast Cancers | MetastaticПодробнее
Spotlight Poster Discussion: "Optimizing use of HER2 therapies in metastatic HER2+ breast..."Подробнее
